) has obtained the approval of the U.S. Food and Drug
Administration (FDA) for its Arrow UltraQuick peripheral nerve
block (PNB) needles. The UltraQuik needles enhance block success
for single-injection PNBs using the ultrasound approach.
This needle, along with the StimuQuick and StimuQuick Echo
needles from the Anesthesia and Respiratory division under the
larger Critical Care unit, provides a wide range of clinical
solutions for performing PNBs. The company's anesthetic and
respiratory product lines are contributing positively to the
growth of the Critical Care business, which grew by 4.5% on a
constant currency basis in the last reported quarter.
Teleflex has embarked on enhancing its Arrow brand ever since
the acquisition of Arrow International in 2007. The acquisition
has significantly bolstered single-use product offerings for
critical care from Teleflex and expanded its global reach.
Limerick, Pennsylvania-based Teleflex is a global leader in
medical devices used in critical care and surgery. The company
focuses on profitable and consistent growth and is expected to
yield results. The company envisages its sales growth to surpass
the market growth. It also plans to gain market share in key
Product innovation is the driving force for Teleflex.
Contributions from new products in the most recent quarter
reflect gains from the company's increased focus on research and
development. However, the failure to protect its intellectual
property and lower-than-expected market adoption of the new
products may hinder its growth.
Teleflex operates in a highly competitive medical devices
industry and the implementation of the medical devices tax from
this year is likely to put additional pressure on its bottom
line. Further, the company operates in a stringent regulatory
environment. The demand for its products is susceptible to
healthcare reimbursement systems in the domestic as well as the
The stock carries a Zacks Rank #3 (Hold). Medical instrument
companies, such as
Cantel Medical Corp.
, Inc. (
) with Zacks Rank #1 (Strong Buy), are expected to do well.
CANTEL MED CORP (CMN): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
DELCATH SYS INC (DCTH): Free Stock Analysis
TELEFLEX INC (TFX): Free Stock Analysis
To read this article on Zacks.com click here.